Halobetasol-Lidocaine Formulation
(CITI-002)
Prescription Strength Topical for Symptomatic Hemorrhoid Treatment
Halo-Lido Overview
Citius Pharmaceuticals is developing a proprietary topical formulation of halobetasol and lidocaine using 505(b)(2) to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.

Summary of Opportunity
Although there are numerous prescription and over-the-counter (OTC) products commonly used to treat hemorrhoids, none currently possess safety and efficacy data generated from rigorously-conducted clinical trials. Citius believes its halobetasol-lidocaine product will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy in treating hemorrhoids, an uncomfortable and often recurring condition.